Jørgen Thorball

STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLAs first patient subgroup-matched precision treatment. Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.

Bio-Me is transforming microbiome analysis by making it possible to analyze hundreds of samples in less than a day, with high resolution and reproducibility and at an affordable cost. Combined with an exclusive biobank and extensive patient database, Bio-Me’s Precision Microbiome Profiling platform (PMP™) enables the development of clinical tests that will improve health and well-being worldwide.

RetiPharma is a Biotech company focused on developing novel treatments for neurodegenerative eye diseases and forward & backward translatability

STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLAs first patient subgroup-matched precision treatment. Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.

Bio-Me is transforming microbiome analysis by making it possible to analyze hundreds of samples in less than a day, with high resolution and reproducibility and at an affordable cost. Combined with an exclusive biobank and extensive patient database, Bio-Me’s Precision Microbiome Profiling platform (PMP™) enables the development of clinical tests that will improve health and well-being worldwide.

RetiPharma is a Biotech company focused on developing novel treatments for neurodegenerative eye diseases and forward & backward translatability

Ophiuchus Technologies is the first globally to repair the brain and spinal cord by mimicking the salamander’s regeneration capacity through its game-changing DrSC™ technology in human application. DrSC™ Neural are organ-specific and are the first neural stem cells produced that have full competence for functional integration in the brain and spinal cord. First indications: Spinal Cord Injury and Traumatic Brain Injury. Clinical development: First-in-man clinical trial in Spinal Cord Injury approved; planned patient recruitment to start in summer of 2014. The unique DrSC™ technology permits the creation of Directly reprogrammed Stem Cells (DrSC™) from a patient’s own (autologous) mature, accessible cells (e.g. blood cells) without going through a pluripotency state, which essentially eliminates the risk of tumor formation and overcomes a number of safety challenges. Ophiuchus Technologies AG is a NOVAGENESIS company based out of Switzerland. (“Ophiuchus”; pronounced [äˈfiSHəs], the 13th star sign representing the god / source of medicine and rebirth.)

1CryoBio AG is a privately held company in the field of consumables for research and medical use, located at the Technopark of Lucerne in Root D4, Switzerland. 1CryoBio AG develops, produces and markets innovative plastic labware for cryogenic storage based on Danish design and Swiss quality. The company is backed by renowned investors. 1CryoBio’s first product, called FlexiQuot, is a revolutionary patent-protected system for cryogenic storage of biological material. It is the first dividable cryogenic tube in the world with a total volume of 5 ml that can be separated into 5 aliquots of 1 ml. Each aliquot has a label on to avoid sample mix-ups. Using a snapping tool and a holder exactly for the dimensions of the tube, the user breaks off the aliquot that he needs, caps it and puts the rest back in the freezer without having to thaw the content of the entire vial for an analysis. This way, freezing - thawing issue and contamination of the sample are avoided, keeping its quality and stability. FlexiQuot combines the flexibility of multiple small cryogenic vials with the storage and cost effectiveness of one large cryotube. It also eliminates other basic disadvantages of fixed volume cryogenic tubes, such as human errors in labeling and storage or sub-optimal use of precious cryogenic storage space. Overall, FlexiQuot optimizes frozen sample storage. 1CryoBio is constantly striving to improve its existing products and to develop exciting new products with a strong pipeline to address the constantly evolving needs of labs to improve cost and work flow efficiency. Initially, other volumes and versions of FlexiQuot are expected in the near future. But this is only the beginning. 1CryoBio intends to bring a true revolution in cryopreservation, starting with FlexiQuot and continuing with a series of envisaged new products. All these products are expected to change the field of cryopreservation in a few years.